Clinical Trials for Immunova

Explore 17 clinical trials worldwide

Showing 1-17 of 17 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Immunova

Clinical Trials (17)

NCT07188844
An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
PHASE2Enrolling by invitation
108 participants
Started: Aug 28, 2025 · Completed: Nov 30, 2028
1 condition1 sponsor30 locations
NCT06979531
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
PHASE2Recruiting
180 participants
Started: Jun 30, 2025 · Completed: Jul 31, 2028
1 condition1 sponsor3 locations
NCT07018323
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
PHASE2Recruiting
210 participants
Started: Jun 19, 2025 · Completed: May 31, 2027
1 condition1 sponsor22 locations
NCT07039916
Study to Access the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
PHASE3Recruiting
231 participants
Started: May 27, 2025 · Completed: Dec 31, 2027
1 condition1 sponsor25 locations
NCT07032662
IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
PHASE2Recruiting
162 participants
Started: Mar 18, 2025 · Completed: May 31, 2030
1 condition1 sponsor134 locations
NCT06980805
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
PHASE2Recruiting
56 participants
Started: Feb 19, 2025 · Completed: Apr 30, 2027
2 conditions1 sponsor70 locations
NCT06754462
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
PHASE2Recruiting
120 participants
Started: Jan 10, 2025 · Completed: Sep 30, 2027
1 condition1 sponsor82 locations
NCT06727604
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
PHASE2Recruiting
240 participants
Started: Dec 17, 2024 · Completed: Jun 30, 2028
1 condition1 sponsor78 locations
NCT05907668
A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease
PHASE2Active, not recruiting
35 participants
Started: May 15, 2023 · Completed: Jul 31, 2025
1 condition1 sponsor1 location
NCT05524571
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
PHASE3Active, not recruiting
100 participants
Started: Jan 5, 2023 · Completed: Dec 31, 2025
1 condition1 sponsor45 locations
NCT05581199
To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
PHASE2Active, not recruiting
277 participants
Started: Dec 15, 2022 · Completed: Jan 31, 2027
1 condition1 sponsor116 locations
NCT05517421
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
PHASE3Active, not recruiting
100 participants
Started: Nov 23, 2022 · Completed: Dec 31, 2025
1 condition1 sponsor93 locations
NCT05517447
Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease
PHASE3Recruiting
180 participants
Started: Nov 6, 2022 · Completed: Aug 31, 2026
1 condition1 sponsor55 locations
NCT05403541
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
PHASE3Active, not recruiting
240 participants
Started: Jun 27, 2022 · Completed: Apr 30, 2025
1 condition1 sponsor105 locations
NCT04920617
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
PHASE2Recruiting
102 participants
Started: Jun 18, 2021 · Completed: Apr 30, 2025
2 conditions2 sponsors50 locations
NCT03836352
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
PHASE2Active, not recruiting
184 participants
Started: Dec 21, 2018 · Completed: Dec 31, 2023
5 conditions2 sponsors23 locations
NCT03029403
Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer
PHASE2Active, not recruiting
47 participants
Started: Feb 12, 2018 · Completed: Apr 12, 2026
4 conditions3 sponsors1 location